Knowledge Check

Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.

Log in to access
Last updated: June 16, 2026Bookmark

Epilepsy is a chronic neurological disorder characterised by idiopathic (75%), recurrent (2 or more), unprovoked seizures. Patients with epilepsy are usually physically normal and asymptomatic between events.

It affects 1% of all people by age 20 and 3% by age 75%.

Specific epilepsy syndromes

SyndromeAge of OnsetKey Seizure Type(s)Distinguishing FeaturesEEG FindingsPrognosis
Childhood Absence Epilepsy (CAE)4–10 yrsAbsence seizuresBrief staring, no postictal confusion, triggered by hyperventilation3 Hz spike-and-waveGood, often resolves
Juvenile Myoclonic Epilepsy (JME)AdolescenceMyoclonic, GTCS, ± absenceMorning jerks, triggered by sleep deprivationGeneralized polyspike-and-waveLifelong, well-controlled
West Syndrome<1 yrInfantile spasmsDevelopmental regression, flexor/extensor spasmsHypsarrhythmiaPoor
Lennox–Gastaut Syndrome1–8 yrsTonic, atonic, atypical absenceDrop attacks, intellectual disabilitySlow spike-and-wave (<3 Hz)Poor, refractory
Benign Rolandic Epilepsy3–13 yrsFocal (face)Facial twitching, drooling, occurs during sleepCentrotemporal spikesExcellent
Juvenile Absence EpilepsyAdolescenceAbsence + Generalised tonic clonicLess frequent absences than CAE3–4 Hz spike-and-waveModerate
Generalized Tonic-Clonic SeizuresAnyGeneralized tonic clonicTonic → clonic → postictal confusionGeneralized dischargesVariable
Temporal Lobe EpilepsyAnyFocal impaired awarenessAura (déjà vu, fear), automatismsTemporal lobe abnormalitiesVariable
Frontal Lobe EpilepsyAnyFocal motorBrief, frequent, bizarre movements, often during sleepFrontal lobe abnormalitiesVariable
Dravet SyndromeInfancyFebrile → multiple typesDevelopmental delay, prolonged seizures, SCN1A mutationGeneralized abnormalitiesPoor
Febrile Seizures6 mo–5 yrsGeneralizedFever-associated, usually briefNormalExcellent
  • Risk factors
    • Genetics
      • Idiopathic epilepsy is caused bygenes affecting ion channels and neurotransmitters
      • Syndromic epilepsy can occur in Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis complex
    • Cerebral malformations such as cortical dysplasia or hippocampal sclerosis
    • Neurocutanous syndrome such as Sturge-Weber syndrome and neurofibromatosis
    • Stroke and vascular disease
    • Traumatic brian injury
    • Infections
    • Metabolic disorder such as mtochondrial disease, pyridoxine dependency, and phenylketonuria
    • Autoimmune disease such as SLE
    • Chronic inflammation
  • Pathophysiology
    • Disruption of the balance between excitatory (via NMDA and AMPA receptors) and inhibitory neurotransmitters (via GABA receptors)
    • Ionic channel dysfunction – affects Na+, K+, Ca2_ and Cl- channels
    • Aberrant long-term potentiation (LTP) enhances excitatory synaptic transmission, while impaired long-term depression (LTD) reduces inhibitory control
    • Structural abnormaliteis make it conducive for seizures to be generated
    • Cytokines like IL-1B and TNF-a alter blood-brain barrier permeability, affect ion channel funciton, modify neurotransmitter systems, and cotnribute to neurodegeneration
  • Differentials for epilepsy
  • Investigations
    • Electroencephalogram (EEG) to identify characteristic patterns such as iterictal epileptiform discharges (EEG)
    • Magnetic resonance imaging (MRI) to identify structural abnormalities
    • Video-EEG monitoring to correlate observed behaviour during a seizure and changes in brain electrical activity. It combines video recording with continuous EEG montiroing for 5 – 7 days.
    • PET/SPECT scan to localizse the seizure focus
  • Treatment after the second unexplained seizure
    • Refer for an EEG
      • 30-minute EEG
      • 5-7 day continuous video EEG
    • Antiepileptic drugs (AEDs)
      • Carbamazepine or lamotrigine for focal seizures or generalised tonic-clonic seizures
      • Carbamazepine or lamotrigine for focal onset seizures in children
      • Levetiracetam or valproate for generalized onset seizures in children
      • Dual therapy with second-line medications ( sodium valproate, lamotrigine, levetiracetam and topiramate) if treatment is refractory to a single AED
    • Symptom monitoring for patients with well-documented focal lesions
    • Surgery for patients with well documented focal lesions
    • Patient education while on anti-epileptic drugs
      • Avoid becoming drunk, especially drinking sprees during weekends
      • Eat at regular intervals
      • Manage stress (physical or mental) as it may precipitate fits
      • Avoid sleep deprivation
      • Never swim alone
      • Avoid operating heavy or sharp edged machinery
      • To prevent burns, make protective shields around braziers (”Jikos”)
    • Considerations before starting antiepileptic drugs for women of reproductive age
      • Pregnancy determination test
      • Counseling (contraception, pregnancy, and breastfeeding)
        • Most AEDs except Carbamazepine and Valproate are present in breast milk
        • Lamotrigine is not harmful to infants
        • Enzyme-inducing AEDs may make progesterone-only contraceptives unreliable
        • Oestrogen-containing contraceptives lower Lamotrigine levels and dosage might need to be increased
        • Strictly avoid Valporate and polytherapy before and during conception
        • Do not take a pregnant woman off her antiepileptic drugs. Instead, supplement with folate 5mg/d to decrease the risk of neural tube defects.
  • Complications
    • Status epilepticus
    • Sudden unexpected death in epilepsy (SUDEP) can occur in uncontrolled epilepsy as a result of nocturnal seizure-associated apnoea or asystole.
    • Injury from seizures
    • Drug-related complications: hepatotoxicity, teratogenicity, bone marrow suppression, and skin rashes
    • Depression and axiety
    • Cognitive impairment
    • Social isolation
    • Educational underachievement and unemployment
    • Driving restriction – must be seizure-free for a year before they can apply for a driving license
Reference Intervals ›
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator ›

Leave a Reply